Evidence map›Paper›PMID 41181736›Full record

ArticleCureus2025

Effect of Continuous Renal Replacement Therapy Using oXiris Hemofilter in a Critically Ill Patient With Sepsis and Acute Respiratory Distress Syndrome.

Osama Sobh, Hussein Soueidan, Afrah Alatifi, Mohamed T Yassin, Marwa M Elmaghrabi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Osama SobhCritical Care Medicine, King Saud Hospital, Unaizah, SAU.
Hussein SoueidanResearch and Development, Med Surg Solutions, Riyadh, SAU.
Afrah AlatifiCritical Care Medicine, King Saud Hospital, Unaizah, SAU.
Mohamed T YassinBotany and Microbiology, King Saud University, Riyadh, SAU.
Marwa M ElmaghrabiResearch, Center of Excellence for Research in Regenerative Medicine and Applications, Alexandria University, Alexandria, EGY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS) and sepsis represent severe and often life-threatening conditions, especially in critically ill patients with multiple comorbidities. This case report details the management of a 59-year-old male patient with a complicated medical history, including ischemic heart disease (IHD), hypertension (HTN), diabetes mellitus (DM), and chronic kidney disease (CKD). The patient was admitted to the intensive care unit (ICU) due to acutely decompensated heart failure (HF) and subsequent sepsis, leading to ARDS. His treatment involved initiating continuous renal replacement therapy (CRRT) using the oXiris filter (Baxter International Inc., Deerfield, IL, USA), known for its ability to adsorb cytokines. The oXiris filter was employed as part of a multifaceted approach to manage the patient's acute kidney injury (AKI) in the context of septic shock and a cytokine storm. Remarkably, no adverse effects were noted, and the patient demonstrated clinical improvement. This case supports the feasibility and safety of using CRRT with the oXiris filter in septic patients with AKI and a cytokine storm, providing an effective adjunctive treatment strategy. This technique may offer potential benefits in managing critically ill patients with complex comorbid conditions, highlighting its possible role in improving outcomes for similar clinical scenarios.

Indexed as

absorbing filtersacute kidney injuryblood purificationcontinuous renal replacement therapy (crrt)critical illnessfluid balanceoxiris hemofilterseptic shock

Identifiers

PMID41181736
PMCPMC12579553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.